Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome.
Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome.
复制标题
DOI：
--
复制
发表时间：
2003-04
期刊：
影响因子：
11.2
通讯作者：
R. Camp;M. Dolled-Filhart;B. King;D. Rimm
中科院分区：
文献类型：
--
作者：
R. Camp;M. Dolled-Filhart;B. King;D. Rimm
使用300例乳腺癌和84例正常乳腺上皮样本的组织微阵列队列，我们分析了HER 2/neu表达，并将传统的临床（手动）评分与最近开发的免疫组化染色定量测量系统（AQUA）进行了比较。正如预期的那样，两种方法都确定了一个群体（10-15%）的高HER 2表达肿瘤与穷人的30年疾病相关的生存。使用AQUA分析，我们发现正常上皮表达低但可检测水平的HER 2，并且17.5%的肿瘤表现出类似的低水平HER 2表达。该低分组无法通过手动评分进行定义。令人惊讶的是，HER 2正常肿瘤与HER 2过表达肿瘤一样具有侵袭性。我们的研究表明，原位定量测量HER 2将乳腺肿瘤分为三个表达水平：正常，中等和高水平，其中正常和高水平均与更差的结果相关。
Using a tissue microarray cohort of 300 breast cancers and 84 samples of normal breast epithelium, we analyzed HER2/neu expression and compared traditional clinical (manual) scoring with a recently developed system for the quantitative measurement of immunohistochemical stains (AQUA). As expected, both methods identified a population (10-15%) of high-HER2-expressing tumors with poor 30-year disease-related survival. Using AQUA analysis, we found that normal epithelium expresses a low but detectable level of HER2 and that 17.5% of tumors exhibit similar low-level HER2 expression. This low group was not definable by manual scoring. Surprisingly, HER2-normal tumors were as aggressive as HER2-overexpressing tumors. Our studies suggest that in situ quantitative measurement of HER2 stratifies breast tumors into three expression levels: normal, intermediate, and high, where both normal and high levels are associated with a worse outcome.